Key result
Adjusted indirect comparison showed that rivaroxaban was superior to dabigatran in preventing venous thromboembolism after elective orthopaedic surgery.
Why the study?
Does dabigatran or rivaroxaban prevent venous thromboembolism compared to enoxaparin in patients undergoing elective orthopaedic surgery?
Meta-Analysis
Does dabigatran or rivaroxaban prevent venous thromboembolism compared to enoxaparin in patients undergoing elective orthopaedic surgery?
Rivaroxaban may be more effective than dabigatran for prevention of VTE after elective orthopaedic surgery but might also slightly increase the risk of haemorrhage.
Answers are grounded in this paper and cite their sources.
Supports preferring rivaroxaban over dabigatran for VTE prophylaxis after orthopaedic surgery; extends indirect evidence from enoxaparin-controlled trials.
WHAT IS KNOWN AND OBJECTIVE: Dabigatran and rivaroxaban are new oral anticoagulants for thromboprophylaxis after elective orthopaedic surgery. We aimed to systematically compare their relative benefits and harms through meta-analysis, and adjusted indirect comparison. METHODS: We searched PubMed, EMBASE, trial registries and regulatory documents through May 2009 for randomized controlled trials (RCTs) of dabigatran (150 and 220 mg daily) and rivaroxaban (10 mg daily) compared with enoxaparin (40-60 mg daily) in elective orthopaedic surgery. We used random effects meta-analysis to calculate pooled relative risks (RRs) and 95% confidence intervals (95% CI) for the outcomes of total venous thromboembolism, VTE (deep venous thrombosis, non-fatal pulmonary embolism and all-cause mortality), and haemorrhagic adverse events (major and clinically relevant non-major bleeds). Adjusted indirect comparison was used for the pooled RRs of dabigatran and rivaroxaban with enoxaparin as the common control. RESULTS: Rivaroxaban was superior to enoxaparin for the prevention of venous thromoboembolism (RR 0.56, 95% CI 0.43-0.73, P<0.0001), with a trend for increased haemorrhage (RR 1.26, 95% CI 0.94-1.69, P=0.13). Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1.12, 95% 0.97-1.29, P=0.12), and did not reduce haemorrhage risk (RR 1.10, 95% 0.90-1.35, P=0.32). Adjusted indirect comparison showed that rivaroxaban was superior to dabigatran in preventing VTE, RR 0.50 (95% CI 0.37-0.68), but with a slight trend towards increased haemorrhage RR 1.14 (95% CI 0.80-1.64). WHAT IS NEW AND CONCLUSION: Rivaroxaban may be more effective than dabigatran for prevention of VTE after elective orthopaedic surgery but might also slightly increase the risk of haemorrhage.
No takes yet. Share an insight, caveat, or question.
Loke et al. (2010) conducted a meta-analysis in Elective orthopaedic surgery (thromboprophylaxis). Rivaroxaban vs. Dabigatran (150 and 220 mg daily) was evaluated on Total venous thromboembolism (deep venous thrombosis, non-fatal pulmonary embolism and all-cause mortality) (RR 0.50, 95% CI 0.37-0.68). Adjusted indirect comparison showed that rivaroxaban was superior to dabigatran in preventing venous thromboembolism after elective orthopaedic surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: